Kindred Biosciences Stock Price, Forecast & Analysis (NASDAQ:KIN)

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) posted its quarterly earnings results on Wednesday, March, 6th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.04. The biopharmaceutical company earned $1.33 million during the quarter, compared to the consensus estimate of $1.44 million. Kindred Biosciences had a negative return on equity of 55.46% and a negative net margin of 1,583.00%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Kindred Biosciences.

Kindred Biosciences will be holding an earnings conference call on Tuesday, November 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 Wall Street analysts have issued 1-year target prices for Kindred Biosciences' stock. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' stock price to reach $14.81 in the next twelve months. This suggests a possible upside of 75.5% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Press coverage about KIN stock has trended very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kindred Biosciences earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a increase in short interest in September. As of September 30th, there was short interest totalling 930,300 shares, an increase of 9.6% from the August 30th total of 848,700 shares. Based on an average daily volume of 177,800 shares, the short-interest ratio is currently 5.2 days. Currently, 2.5% of the company's shares are sold short. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Epizyme (EPZM), Zymeworks (ZYME), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Innoviva (INVA), BELLUS Health (BLUSF), ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), AnaptysBio (ANAB), Y-mAbs Therapeutics (YMAB), ZEALAND PHARMA/S (ZEAL), Endo International (ENDP) and Stoke Therapeutics (STOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), Cara Therapeutics (CARA), Opko Health (OPK), TherapeuticsMD (TXMD), Celgene (CELG), Corbus Pharmaceuticals (CRBP) and Global Blood Therapeutics (GBT).

Kindred Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dalton Greiner Hartman Maher & Co. (0.36%), Teton Advisors Inc. (0.09%), Gabelli Funds LLC (0.04%) and Tower Research Capital LLC TRC (0.02%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

KIN stock was purchased by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Tower Research Capital LLC TRC , Gabelli Funds LLC and Teton Advisors Inc.. View Insider Buying and Selling for Kindred Biosciences.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $8.44.

Kindred Biosciences has a market capitalization of $329.67 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]